Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25071750 | 1.00 | ERN1 (1.00) | ERN1MAPK10 | |
| Hydrochloric Acid SCHEMBL27237796 | 0.99 | ERN1 (0.99) | ERN1MAPK10 | |
| Hydrochloric Acid SCHEMBL27237801 | 0.99 | ERN1 (0.99) | ERN1MAPK10 | |
| SCHEMBL30142988 | 0.96 | ERN1 (0.92) | ERN1 | |
| SCHEMBL25072046 | 0.96 | ERN1 (0.92) | ERN1 | |
| SCHEMBL25071962 | 0.96 | ERN1 (0.92) | ERN1MAPK10 | |
| SCHEMBL21908932 | 0.96 | ERN1 (0.92) | ERN1MAPK10 | |
| SCHEMBL30143033 | 0.96 | ERN1 (0.92) | ERN1MAPK10 | |
| SCHEMBL25072043 | 0.95 | ERN1 (0.91) | ERN1 | |
| SCHEMBL21909233 | 0.95 | ERN1 (0.91) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | XBP1, ERN1, ESR2 | ERN1 2/4885MAPK10 1353/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | ERN1 2/4885MAPK10 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.